Jane Street’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-237,128
| Closed | -$9.18M | – | 9786 |
|
|
2025
Q1 | $8.07M | Sell |
237,128
-189,689
| -44% | -$8.04M | ﹤0.01% | 2270 |
|
|
2024
Q4 | $16.8M | Buy |
426,817
+255,387
| +149% | +$12.1M | ﹤0.01% | 1409 |
|
|
2024
Q3 | $8.05M | Sell |
171,430
-178,501
| -51% | -$9.06M | ﹤0.01% | 2160 |
|
|
2024
Q2 | $18.9M | Buy |
349,931
+174,859
| +100% | +$10.1M | ﹤0.01% | 1367 |
|
|
2024
Q1 | $11.9M | Sell |
175,072
-299,936
| -63% | -$21.5M | ﹤0.01% | 1648 |
|
|
2023
Q4 | $29.7M | Buy |
475,008
+349,887
| +280% | +$19.3M | 0.01% | 972 |
|
|
2023
Q3 | $5.68M | Buy |
125,121
+28,650
| +30% | +$1.48M | ﹤0.01% | 2438 |
|
|
2023
Q2 | $5.42M | Sell |
96,471
-37,739
| -28% | -$2.14M | ﹤0.01% | 2615 |
|
|
2023
Q1 | $6.07M | Buy |
134,210
+63,620
| +90% | +$3.09M | ﹤0.01% | 2188 |
|
|
2022
Q4 | $2.87M | Buy |
70,590
+64,020
| +974% | +$3.4M | ﹤0.01% | 3290 |
|
|
2022
Q3 | $429K | Sell |
6,570
-104,845
| -94% | -$7.6M | ﹤0.01% | 6963 |
|
|
2022
Q2 | $6.77M | Buy |
111,415
+24,436
| +28% | +$1.44M | ﹤0.01% | 2229 |
|
|
2022
Q1 | $5.46M | Sell |
86,979
-206,099
| -70% | -$12.9M | ﹤0.01% | 2892 |
|
|
2021
Q4 | $22.2M | Buy |
293,078
+43,882
| +18% | +$3.83M | 0.01% | 1126 |
|
|
2021
Q3 | $27.9M | Sell |
249,196
-162,965
| -40% | -$20.5M | 0.01% | 906 |
|
|
2021
Q2 | $66.7M | Buy |
412,161
+47,075
| +13% | +$5.73M | 0.03% | 433 |
|
|
2021
Q1 | $44.5M | Buy |
365,086
+180,737
| +98% | +$27.3M | 0.02% | 537 |
|
|
2020
Q4 | $28.2M | Buy |
184,349
+175,906
| +2,083% | +$20.8M | 0.01% | 677 |
|
|
2020
Q3 | $706K | Buy |
8,443
+3,549
| +73% | +$315K | ﹤0.01% | 4646 |
|
|
2020
Q2 | $360K | Sell |
4,894
-21,656
| -82% | -$1.27M | ﹤0.01% | 5562 |
|
|
2020
Q1 | $1.13M | Buy |
26,550
+20,485
| +338% | +$1.06M | ﹤0.01% | 2669 |
|
|
2019
Q4 | $370K | Buy |
+6,065
| New | +$331K | ﹤0.01% | 4039 |
|
|
2019
Q3 | – | Sell |
-11,907
| Closed | -$561K | – | 5149 |
|
|
2019
Q2 | $561K | Buy |
11,907
+5,646
| +90% | +$226K | ﹤0.01% | 3431 |
|
|
2019
Q1 | $224K | Sell |
6,261
-33,013
| -84% | -$1.14M | ﹤0.01% | 4545 |
|
|
2018
Q4 | $1.12M | Sell |
39,274
-48,352
| -55% | -$1.68M | ﹤0.01% | 2395 |
|
|
2018
Q3 | $3.89M | Buy |
87,626
+77,674
| +780% | +$4.07M | 0.01% | 1249 |
|
|
2018
Q2 | $585K | Sell |
9,952
-9,421
| -49% | -$537K | ﹤0.01% | 3421 |
|
|
2018
Q1 | $886K | Buy |
+19,373
| New | +$800K | ﹤0.01% | 2818 |
|
Other funds holding CRSP
AIM
OAG
GP
SOCM
Jane Street's CRSP Position: Q2 2025 in Review
Jane Street sold out of CRISPR Therapeutics (CRSP) in Q2 2025, closing a stake of 237,128 shares — an estimated $9.18M sold.
Jane Street first reported a position in CRSP in Q1 2018 and held it in 28 quarters. The position peaked at $66.7M in Q2 2021. 433 funds tracked by Wall St. Rank hold CRSP as of Q2 2025.
- Jane Street reported no remaining CRISPR Therapeutics position as of Q2 2025 after selling out during the quarter.
- Jane Street sold 237,128 CRISPR Therapeutics shares in Q2 2025, an estimated $9.18M.
- Jane Street first reported a position in CRISPR Therapeutics in Q1 2018 and held it in 28 quarters.
- Jane Street's CRISPR Therapeutics position peaked at $66.7M in Q2 2021.
- 433 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2025.
Based on Jane Street's 13F filing for Q2 2025, filed 14 Aug 2025.